JP2025509352A - Ｃｏｖｉｄ－１９の予防に使用するための組み換え型ニューカッスル病ウイルスおよび免疫原性組成物 - Google Patents

Ｃｏｖｉｄ－１９の予防に使用するための組み換え型ニューカッスル病ウイルスおよび免疫原性組成物 Download PDF

Info

Publication number
JP2025509352A
JP2025509352A JP2024553586A JP2024553586A JP2025509352A JP 2025509352 A JP2025509352 A JP 2025509352A JP 2024553586 A JP2024553586 A JP 2024553586A JP 2024553586 A JP2024553586 A JP 2024553586A JP 2025509352 A JP2025509352 A JP 2025509352A
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
protein
seq
cov
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553586A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509352A5 (enExample
Inventor
パレーゼ、ピーター
サストレ、アドルフォ ガルシア
クラマー、フロリアン
サン、ウェイナ
ドミンゲス、アイリーン ゴンザレス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Icahn School of Medicine at Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School of Medicine at Mount Sinai filed Critical Icahn School of Medicine at Mount Sinai
Publication of JP2025509352A publication Critical patent/JP2025509352A/ja
Publication of JP2025509352A5 publication Critical patent/JP2025509352A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024553586A 2022-03-10 2023-03-09 Ｃｏｖｉｄ－１９の予防に使用するための組み換え型ニューカッスル病ウイルスおよび免疫原性組成物 Pending JP2025509352A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263318640P 2022-03-10 2022-03-10
US63/318,640 2022-03-10
PCT/US2023/064063 WO2023173032A2 (en) 2022-03-10 2023-03-09 Recombinant newcastle disease viruses and immunogenic compositions for use in preventing covid-19

Publications (2)

Publication Number Publication Date
JP2025509352A true JP2025509352A (ja) 2025-04-11
JP2025509352A5 JP2025509352A5 (enExample) 2026-03-13

Family

ID=87936013

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553586A Pending JP2025509352A (ja) 2022-03-10 2023-03-09 Ｃｏｖｉｄ－１９の予防に使用するための組み換え型ニューカッスル病ウイルスおよび免疫原性組成物

Country Status (11)

Country Link
US (1) US20250186578A1 (enExample)
EP (1) EP4489779A4 (enExample)
JP (1) JP2025509352A (enExample)
KR (1) KR20240161963A (enExample)
CN (1) CN119317446A (enExample)
AU (1) AU2023231285A1 (enExample)
CA (1) CA3245533A1 (enExample)
CL (1) CL2024002683A1 (enExample)
CO (1) CO2024012344A2 (enExample)
MX (1) MX2024011049A (enExample)
WO (1) WO2023173032A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5603012B2 (ja) * 2005-12-02 2014-10-08 トヘ モウント シナイ スクール オフ メディシネ オフ ニューヨーク ウニベルシトイ 非天然表面タンパク質を提示するキメラウイルス及びその使用
WO2021226348A2 (en) * 2020-05-07 2021-11-11 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease virus expressing sars-cov-2 spike protein and uses thereof
EP4408463A4 (en) * 2021-09-30 2026-03-18 Icahn School Med Mount Sinai Recombinant Newcastle Disease Virus Expressing a SARS-CoV-2 Delta Variant Spike Protein and Its Uses

Also Published As

Publication number Publication date
KR20240161963A (ko) 2024-11-13
US20250186578A1 (en) 2025-06-12
EP4489779A2 (en) 2025-01-15
WO2023173032A3 (en) 2023-10-12
MX2024011049A (es) 2024-09-18
WO2023173032A2 (en) 2023-09-14
CN119317446A (zh) 2025-01-14
CL2024002683A1 (es) 2025-01-03
CA3245533A1 (en) 2023-09-14
AU2023231285A1 (en) 2024-07-25
CO2024012344A2 (es) 2024-12-30
EP4489779A4 (en) 2026-05-13

Similar Documents

Publication Publication Date Title
CN111088283B (zh) mVSV病毒载体及其病毒载体疫苗、一种基于mVSV介导的新冠肺炎疫苗
ES2929942T3 (es) Vacunas contra el virus de la gripe y sus usos
US20200377908A1 (en) Parainfluenza virus 5 based vaccines
JP2023524990A (ja) ＳＡＲＳ－ＣｏＶ－２スパイクタンパク質を発現する組換えニューカッスル病ウイルス及びその使用
JP6324725B2 (ja) 発現系
US20250041402A1 (en) Recombinant newcastle disease virus expressing spike protein of sars-cov-2 delta variant and uses thereof
US20250228929A1 (en) Recombinant newcastle disease viruses and immunogenic compositions for use in immunizing against sars-cov-2 omicron variant
CN117098551A (zh) 编码截短的ns1蛋白和sars-cov受体结合域的流感病毒
US20250186578A1 (en) Recombinant newcastle disease viruses and immunogenic compositions for use in preventing covid-19
Ljungberg et al. DNA vaccination of ferrets with chimeric influenza A virus hemagglutinin (H3) genes
Le et al. Induction of influenza-specific mucosal immunity by an attenuated recombinant Sendai virus
US20250250304A1 (en) Recombinant newcastle disease virus expressing lassa virus gp or np, and uses thereof
KR101908905B1 (ko) 인플루엔자 바이러스의 h9 및 h5의 다중 아형에 대한 교차 면역반응을 형성하는 신규한 재조합 인플루엔자 바이러스 및 이를 포함하는 백신
RU2680537C1 (ru) Лентивирусная плазмида (варианты), способ ее получения (варианты), набор праймеров для получения лентивирусного плазмидного вектора (варианты)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241107

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250107

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20250205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260304